Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2012

View Archived Issues

Crizotinib effective in patients with NSCLC harboring ROS1 gene rearrangement

MT-102 improves heart function in rat model of cancer cachexia

Canadian and U.S. group patents new antibacterial agents

Astellas Pharma presents novel antifungal agents

Suven Life Sciences discloses new H3 receptor ligands

Eternity Biosciences prepares new protein kinase inhibitors

Japanese scientists synthesize novel agents for thromboembolic disorders

New ghrelin receptor antagonists disclosed by Helsinn Healthcare

Researchers design the first inhibitors of neurotrypsin, a molecular target for sarcopenia

Synthetic Biologics to develop Acinetobacter-targeted MAb therapy

Nektar Therapeutics reports phase Ia data on NKTR-192

Phase II study of PET imaging agent for Alzheimer's disease begins enrollment

Marburg and Ebola virus drug candidates receive FDA fast track designation

Boehringer Ingelheim launches Combivent Respimat for COPD

VIVUS launches once-daily Qsymia in the U.S. for weight management

America Stem Cell receives grant to study platform technology with amniotic fluid-derived stem cells

Shionogi presents first results for the novel antibacterial agent COT-303

Mutabilis receives E.U. funding to support HIVINNOV project for new antiretrovirals

Janssen files BLA for intravenous Simponi in rheumatoid arthritis

SBC-102 demonstrates safety and clinical activity in patients with LAL deficiency

CoLucid reaches agreement with FDA for phase III development of acute migraine therapy

Chugai files for approval of Avastin for additional indication in Japan

Nymox provides update on phase III BPH study

Nippon Shinyaku files application in Japan to extend approval of Tramal

International partnership initiates phase II study of PI3K inhibitor in breast cancer